Aurinia Lupus Candidate Voclosporin Shines in Phase 2b, Despite Patient Deaths

Aurinia Pharmaceuticals has revealed its lupus drug candidate Voclosporin yielded positive top-line results, despite 13 patient deaths in a Phase 2b trial.

In a study involving 265 patients, Voclosporin demonstrated a statistically significant improvement in complete remission after 24 weeks, compared with the standard of care treatment mycophenolate mofetil with placebo.

The patient deaths reported in the trial were deemed unrelated to the therapy, the company said.